Biotie today reported top-line data from a Phase 2 study evaluating its dopamine
beta hydroxylase inhibitor nepicastat (SYN117) in combat veterans suffering from
post-traumatic stress disorder (PTSD). The study was funded by the U.S.
Department of Defense and conducted as an Investigator-initiated study in the
United States using clinical trial material supplied by Biotie.